Medscape6d
Alzheimer Drug Donanemab Gets No-Go From European Regulator
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
News-Medical.Net on MSN17d
Better heart health slows brain aging and lowers dementia risk, study finds
A JAMA Network Open study finds that better cardiovascular health (CVH) in older adults is linked to lower levels of neurodegenerative biomarkers, particularly neurofilament light chain (NfL). These ...
GlobalData on MSN5mon
Roche’s Alzheimer’s test shows high negative predictive value
181 protein assay and apolipoprotein (APO) E4 assay in human blood plasma. The presence of APOE4 signifies a genetic risk of ...
PharmiWeb1mon
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
In December 2024, Eisai requested reconsideration of the decision, proposing to the TGA the same apolipoprotein E4 (ApoE4) noncarrier and heterozygote indication that was agreed by the Medicines and ...